The phase III eXalt3 study compared 225 mg of ensartinib once daily (n = 143) with 250 mg of crizotinib twice daily (n = 147) in 290 patients with ALK-rearranged untreated advanced NSCLC [49]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.